Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased of CytomX Therapeutics, Inc. ("CytomX" or the "Company") (NASDAQ: CTMX) securities between May 17, 2018, and May 13, 2020, inclusive (the "Class Period"). CytomX investors have until July 20, 2020 to file a lead plaintiff motion.
Investors suffering losses on their CytomX investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to firstname.lastname@example.org.
On May 13, 2020, the Company made available abstracts for the Company’s clinical presentations for CX-072 and CX-2009. Results from the PROCLAIM-CX-072 clinical program revealed a response rate of 8.8%, compared to a response rate of 18.5% in patients receiving the combination of CX-072 and ipilimumab. Meanwhile, results from the PROCLAIM-CX-2009 clinical program showed "evidence" of clinical activity at doses at least 4 mg/kg 3x/week, but also suggested a significantly higher rate of serious or greater treatment-related toxicity to the eyes at dose equivalents at least 8 mg/kg 3x/week.
On this news, the Company’s share price fell $5.21 per share, or over 36%, to close at $9.23 per share on May 14, 2020, thereby injuring investors.
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose: (1) that CytomX had downplayed issues with CX-072’s efficacy observed in the PROCLAIM-CX-072 clinical program; (2) that CytomX had similarly downplayed issues with CX-2009’s efficacy and safety observed in the PROCLAIM-CX-2009 clinical program; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you purchased CytomX securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to email@example.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.